Kazuyuki Numakura

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer

Shintaro Narita, Norihiko Tsuchiya, Teruaki Kumazawa et al. · World Journal of Surgical Oncology · 2012 · 101 citations · Full text

Medicine, Oncology, Urology +17

Clinical and Genetic Risk Factors for Posttransplant Diabetes Mellitus in Adult Renal Transplant Recipients Treated with Tacrolimus

Kazuyuki Numakura, Shigeru Satoh, Norihiko Tsuchiya et al. · Transplantation · 2005 · 96 citations

Medicine, Endocrinology, Surgery +17

Impact of the <i>CYP3A4*1G</i> Polymorphism and its Combination with <i>CYP3A5</i> Genotypes on Tacrolimus Pharmacokinetics in Renal Transplant Patients

Masatomo Miura, Shigeru Satoh, H.‐Matsuo Kagaya et al. · Pharmacogenomics · 2011 · 76 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

A high‐fat diet enhances proliferation of prostate cancer cells and activates MCP‐1/CCR2 signaling

Mingguo Huang, Shintaro Narita, Kazuyuki Numakura et al. · The Prostate · 2012 · 66 citations

Medicine, Nutritional Sciences, Oncology +14